Carcinogenesis, Vol. 22, No. 3, 525-527,
March 2001
© 2001 Oxford University Press
SHORT COMMUNICATION |
Slow-release pellets of sodium butyrate do not modify azoxymethane (AOM)-induced intestinal carcinogenesis in F344 rats
Department of Pharmacology of the University of Florence, Viale G. Pieraccini, 6, 50139, Florence,
2 Department of Pathology, S.M. Annunziata Hospital, Florence and
3 Dipartimento di Scienze Chimiche Alimentari Farmaceutiche e Farmacologiche, Università del Piemonte Orientale `Amedeo Avogadro', Italy
Butyrate exerts anti-tumour effects in vitro, but not consistently in vivo. We previously demonstrated that the administration of slow-release gastro-resistant pellets of sodium butyrate increases apoptosis in the colon mucosa of rats, an effect which may protect against carcinogenesis. Therefore, we studied whether the administration of butyrate pellets could protect rats against experimental colon carcinogenesis. Four to 5 week old male F344 rats were fed a high-fat (HF) diet (230 g/kg corn oil w/w) and treated s.c. with two injections (one week apart) of azoxymethane (AOM) at a dose rate of 15 mg/kg body weight or saline. Rats were then divided into two groups: one group received sodium butyrate pellets mixed into the diet (1.5% w/w) for 33 weeks (150 mg butyrate/day) and the second group received the high-fat diet with no butyrate. Administration of sodium butyrate pellets in the diet did not significantly affect colon carcinogenesis: the number of intestinal tumours/rat was 1.6 ± 0.2 in controls and 2.1 ± 0.2 in butyrate-fed rats (means ± SE; P = 0.22, by ANOVA), while the incidence of intestinal tumours was 79 (23/29) and 90% (27/30) in controls and in butyrate-fed rats, respectively (P = 0.29 by Fisher's exact test). The level of apoptosis in the tumours was not affected by butyrate, nor was the expression of p21CIP, a cell cycle-related protein. In conclusion, the current study indicates that butyrate does not protect against AOM-induced colon carcinogenesis in rats.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. C. Crim, L. M. Sanders, M. Y. Hong, S. S. Taddeo, N. D. Turner, R. S. Chapkin, and J. R. Lupton Upregulation of p21Waf1/Cip1 expression in vivo by butyrate administration can be chemoprotective or chemopromotive depending on the lipid component of the diet Carcinogenesis, July 1, 2008; 29(7): 1415 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Lupton Microbial Degradation Products Influence Colon Cancer Risk: the Butyrate Controversy J. Nutr., February 1, 2004; 134(2): 479 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Femia, C. Luceri, P. Dolara, A. Giannini, A. Biggeri, M. Salvadori, Y. Clune, K. J. Collins, M. Paglierani, and G. Caderni Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats Carcinogenesis, November 1, 2002; 23(11): 1953 - 1960. [Abstract] [Full Text] [PDF]
|
|